ERBB2 and breast cancer: Importantly, the evaluation of patients affected by other breast cancer subtypes showed that the 3’MMPs/5’MMPs ratio was also associated with a worse prognosis in hormone receptor-positive breast cancer, but not in patients with HER2-positive disease.